Physician profile
Amy M Buckner
NPI 1669920807
$11,051.48
in general payments reported to CMS, 2019-2025
48 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,255 · 2022: $2,361 · 2023: $2,133 · 2024: $2,252 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,435.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,344.45 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,325.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $807.69 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $636.52 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Abbott Laboratories | $614.71 | 2022-2025 | Freestyle Libre |
| Pfizer INC. | $536.33 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.43 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $373.94 | 2021-2025 | Repatha, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $340.75 | 2021-2025 | Verquvo, Belsomra, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $197.84 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $196.99 | 2021-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $188.25 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $165.85 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $159.34 | 2021-2025 | Xarelto, Spravato |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.